Targis production affected

9 August 2001

Colorado MEDTech, the manufacturer of Urologix' treatment for enlargedprostate cancer, Targis Cooled Thermo Therapy Systems, has received a warning letter from the US Food and Drug Administration regarding quality control at the firm's Longmount, Colorado, facility which has affected its ability to make the product.

MEDTech has said that, due to the manufacturing obstacles, it would go into backorder on the systems. Production of Targis procedure kits, currently manufactured by Urologix, has not been affected.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight